Ubrogepant
Who holds supplier records for Ubrogepant? 5 organisations hold a current record for Ubrogepant: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (4) and China (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Ubrogepant: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/ubrogepant
Reading the evidence
- 5 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
4 of the 5 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 4 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Ubrogepant expires 22 Dec 2041. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (5)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Ubrogepant. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Allsino Pharmaceutical Co., Ltd.ChinaActive DMF 41936 · latest filing Jun 2025
- APITORIA PHARMA PRIVATE LTDIndia Company GMP cert on recordActive DMF 38648 · latest filing Aug 2023
- HONOUR LAB LTDIndia Company GMP cert on recordActive DMF 38498 · latest filing Jun 2023
- MICRO LABS LTDIndia Company GMP cert on recordActive DMF 44023 · latest filing Jun 2026
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 38576 · latest filing Aug 2023
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (2 listed products contain Ubrogepant). The latest listed patent expires 22 Dec 2041. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Ubrogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist used for the acute treatment of migraine with or without aura in adults. It offers a new mechanism for migraine relief by targeting the CGRP pathway.
Chemical identity
- IUPAC name
- (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
- Canonical SMILES
- C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6
- InChIKey
- DDOOFTLHJSMHLN-ZQHRPCGSSA-N
- Synonyms
- Ubrelvy API, ubrelvy, ubrogepant anhydrous
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Calcitonin Gene-related Peptide Receptor Antagonist
- Mechanism of action
- Calcitonin Gene-related Peptide Receptor Antagonists
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Ubrogepant?
5 organisations hold an active US FDA Type II Drug Master File or a CEP for Ubrogepant: Allsino Pharmaceutical Co., Ltd. (China), APITORIA PHARMA PRIVATE LTD (India), HONOUR LAB LTD (India), MICRO LABS LTD (India) and MSN LIFE SCIENCES PRIVATE LIMITED (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Ubrogepant Drug Master Files are active?
Allsino Pharmaceutical Co., Ltd. (DMF 41936), APITORIA PHARMA PRIVATE LTD (DMF 38648), HONOUR LAB LTD (DMF 38498), MICRO LABS LTD (DMF 44023) and MSN LIFE SCIENCES PRIVATE LIMITED (DMF 38576). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Ubrogepant?
Yes. The latest patent listed for an approved US product containing Ubrogepant expires 22 Dec 2041, across 2 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Ubrogepant supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Ubrogepant?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.